Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Ltd, an innovative biotech firm, will conduct an investor webinar to discuss its recent advancements in CAR-iNKT cell therapy for blood cancers and future development plans. The event, headed by CEO Dr. Michael Baker, follows a successful pre-IND meeting with the FDA and outlines the company’s strategy for its cutting-edge iNKT cell therapy platform. A recording of the webinar will be accessible on Arovella’s website for those unable to attend live.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
